



Press Release

Salvatore Butti to become General Manager Italy at STADA Group (EG S.p.A and Crinos S.p.A.)

- Salvatore Butti will join the STADA Group as General Manager for Italy (EG S.p.A. and Crinos S.p.A.) at September 1, 2019. He joins from Teva Italy, where he was leading the Generics and OTC business.
- Longtime General Manager Enrique Häusermann will continue to support as Member of the Italian Supervisory Board.

Bad Vilbel, June 19, 2019 – The STADA Group has nominated a successor for the longtime general manager of EG S.p.A. Enrique Häusermann. Salvatore Butti will take over the operations of STADA's Italian affiliate at September 1, 2019. Häusermann will continue to support as member of the company's Italian Supervisory Board.

Salvatore Butti has more than 35 years of experience in the pharmaceutical industry. He will join EuroGenerics from Teva Italy, where he held the position of Senior Director Generics, OTC and Portfolio since 2013. In the course of his career Butti also held various leadership positions in pharmaceutical companies, e.g., at Sanofi Aventis SpA and Recordati SpA.

"Italy is one of STADA's most important markets in Europe. We are very happy that an experienced leader with a strong track-record like Salvatore has decided to join our company. We are convinced he is the right person to further accelerate our growth in Italy," said Dr. Steffen Wagner, Executive Vice President European Markets at STADA Arzneimittel AG.

"We would like to sincerely thank Enrique Häusermann for more than 20 years of outstanding contribution to STADA's success. He is a true Entrepreneur who built up our Italian affiliate EG S.p.A. and turned it into one of the most successful country organizations in the STADA Group. Therefore, we are happy he will stay involved as a member of the Supervisory Board of the Italian organization," said STADA CEO Peter Goldschmidt.

Executive Board: Peter Goldschmidt (CEO) / Mark Keatley / Miguel Pagan Fernandez
Supervisory Board Chairman: Dr. Günter von Au



About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription Consumer Health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 130 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de

Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de

Or visit us on the Internet at www.stada.com/investor-relations

Executive Board: Peter Goldschmidt (CEO) / Mark Keatley / Miguel Pagan Fernandez

Supervisory Board Chairman: Dr. Günter von Au